113 related articles for article (PubMed ID: 2654447)
1. [Clinical evaluation of CA-50 in cases with colorectal cancer].
Nishida O; Ohmori K; Shiroto H; Sawaguchi Y; Satoh N; Nakajima Y; Manabe K; Kondoh Y; Sano F; Uchino J
Gan No Rinsho; 1989 Apr; 35(5):605-8. PubMed ID: 2654447
[TBL] [Abstract][Full Text] [Related]
2. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of serum tumour markers CEA, CA 50 and CA 242 in colorectal cancer.
Eskelinen M; Pasanen P; Kulju A; Janatuinen E; Miettinen P; Poikolainen E; Tarvainen R; Nuutinen P; Pääkkönen M; Alhava E
Anticancer Res; 1994; 14(3B):1427-32. PubMed ID: 8067718
[TBL] [Abstract][Full Text] [Related]
4. [The value of tumor markers in colorectal cancer].
Peters KM; Grundmann R
Leber Magen Darm; 1989 Jan; 19(1):18-25. PubMed ID: 2927234
[TBL] [Abstract][Full Text] [Related]
5. [Clinical evaluation of a combination assay of CEA, CA-19-9 and TPA in patients with colorectal cancer].
Nishida O; Shiroto H; Satoh N; Nakajima Y; Manabe K; Kondoh Y; Sano F; Uchino J
Gan No Rinsho; 1988 Aug; 34(9):1096-100. PubMed ID: 3172515
[TBL] [Abstract][Full Text] [Related]
6. CA 242 in comparison with established tumour markers in colorectal, pancreatic and lung cancer.
Hasholzner U; Stieber P; Reiter W; Zimmermann A; Hofmann K; Schalhorn A
Anticancer Res; 1999; 19(4A):2477-80. PubMed ID: 10470177
[TBL] [Abstract][Full Text] [Related]
7. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.
Griesenberg D; Nürnberg R; Bahlo M; Klapdor R
Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173
[TBL] [Abstract][Full Text] [Related]
8. EIA versus RIA in detecting carcinoembryonic antigen level of patients with metastatic colorectal cancer.
Wang WS; Lin JK; Lin TC; Chiou TJ; Liu JH; Yen CC; Chen WS; Jiang JK; Yang SH; Wang HS; Chen PM
Hepatogastroenterology; 2004; 51(55):136-41. PubMed ID: 15011849
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
[TBL] [Abstract][Full Text] [Related]
10. Small intestinal mucin antigen (SIMA); a novel tumour marker in colorectal cancer?
Eskelinen M; Pasanen P; Janatuinen E; Pettersson N; Linnane A; Alhava E
Anticancer Res; 1995; 15(5B):2351-6. PubMed ID: 8572651
[TBL] [Abstract][Full Text] [Related]
11. Serological studies on CEA, CA 19-9, STn and SLX in colorectal cancer.
Sato T; Nishimura G; Nonomura A; Miwa K; Miyazaki I
Hepatogastroenterology; 1999; 46(26):914-9. PubMed ID: 10370638
[TBL] [Abstract][Full Text] [Related]
12. Serum tumor markers in colorectal cancer staging, grading, and follow-up.
Plebani M; De Paoli M; Basso D; Roveroni G; Giacomini A; Galeotti F; Corsini A
J Surg Oncol; 1996 Aug; 62(4):239-44. PubMed ID: 8691835
[TBL] [Abstract][Full Text] [Related]
13. [Clinical significance of serum NCC-ST 439 as a tumor marker for colorectal cancer].
Yamaguchi A; Kurosaka Y; Ohta N; Kamata T; Ishida T; Nishimura G; Katoh M; Kosaka T; Yonemura Y; Miyazaki I
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2645-50. PubMed ID: 2549882
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of preoperative serum CA 19.9 assay in patients with colorectal carcinoma.
Diez M; Cerdán FJ; Pollán M; Maestro ML; Ortega MD; Martínez S; Moreno G; Balibrea JL
Anticancer Res; 1994; 14(6B):2819-25. PubMed ID: 7872725
[TBL] [Abstract][Full Text] [Related]
15. [Clinical investigation of carbohydrate antigen CA-50].
Ishii M; Abe O; Okura H; Okazaki N; Kawai T; Saito Y; Sawabu N; Takamizawa Y; Takeuchi T; Niitani H
Gan To Kagaku Ryoho; 1987 Aug; 14(8):2548-55. PubMed ID: 3304170
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of predictive biomarkers for therapeutical strategies in colorectal cancer.
Gasser M; Gerstlauer C; Grimm M; Bueter M; Lebedeva T; Lutz J; Maeder U; Ribas C; Ribas C; Nichiporuk E; Thalheimer A; Heemann U; Thiede A; Meyer D; Waaga-Gasser AM
Ann Surg Oncol; 2007 Apr; 14(4):1272-84. PubMed ID: 17211733
[TBL] [Abstract][Full Text] [Related]
17. CA15-3 serum levels in breast cancer and other malignancies--correlation with clinical course.
Barak V; Carlin D; Sulkes A; Treves A; Biran S
Isr J Med Sci; 1988; 24(9-10):623-7. PubMed ID: 3204010
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of combined CA-19-9 and CEA assay in monitoring recurrences and metastases of colorectal cancer].
Yu BM
Zhonghua Wai Ke Za Zhi; 1992 Dec; 30(12):707-9, 777. PubMed ID: 1339738
[TBL] [Abstract][Full Text] [Related]
19. Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen.
Huber K; Kirchheimer JC; Sedlmayer A; Bell C; Ermler D; Binder BR
Cancer Res; 1993 Apr; 53(8):1788-93. PubMed ID: 8467497
[TBL] [Abstract][Full Text] [Related]
20. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
Chen C; Chen LQ; Yang GL; Li Y
Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]